Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John J Barron

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Journal of Managed Care Pharmacy : JMCP|November 23, 2005
Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims dataJay Margolis, John J Barron, W Daniel Grochulski
Clinical Drug Investigation|May 26, 2007
Quality of care and attributable healthcare costs in diabetic hypertensive patients initiated on calcium antagonist therapyJohn J Barron, Ibrahim Al-Zakwani, Thomas Iarocci
The Oncologist|August 18, 2009
HER2 testing and subsequent trastuzumab treatment for breast cancer in a managed care environmentJohn J Barron, Mark J Cziraky, Thomas Weisman, et al.
Breast Cancer Research and Treatment|August 4, 2007
Assessing the economic burden of breast cancer in a US managed care populationJohn J Barron, Ralph Quimbo, Prashant T Nikam, et al.
Journal of Pediatric Gastroenterology and Nutrition|November 22, 2007
Proton pump inhibitor utilization patterns in infantsJohn J Barron, Hiangkiat Tan, James Spalding, et al.
Journal of Breast Imaging|February 28, 2024
The Association Between Mammography Screening Frequency and Breast Cancer Treatment and Outcomes: A Retrospective Cohort StudyYing Liu, Aliza S Gordon, Michael Eleff, et al.
Plos One|March 29, 2018
Length of hospitalization and mortality for bleeding during treatment with warfarin, dabigatran, or rivaroxabanBlake Charlton, Gboyega Adeboyeje, John J Barron, et al.
JCO Oncology Practice|March 11, 2020
Use of Optimal Evidence-Based Anticancer Drug Regimens in Physician Offices Versus Hospital Outpatient FacilitiesEzra Fishman, Michael J Fisch, Ying Liu, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 22, 2022
Immune checkpoint inhibitors: immune-related adverse events, healthcare utilization, and costs among commercial and Medicare Advantage patientsKrishna S Gunturu, Timothy T Pham, Sonali Shambhu, et al.
The American Journal of Managed Care|September 27, 2012
Impact of medical homes on quality, healthcare utilization, and costsAndrea DeVries, Chia-Hsuan Winnie Li, Gayathri Sridhar, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Journal of Managed Care Pharmacy : JMCP|November 23, 2005
Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims dataJay Margolis, John J Barron, W Daniel Grochulski
Clinical Drug Investigation|May 26, 2007
Quality of care and attributable healthcare costs in diabetic hypertensive patients initiated on calcium antagonist therapyJohn J Barron, Ibrahim Al-Zakwani, Thomas Iarocci
The Oncologist|August 18, 2009
HER2 testing and subsequent trastuzumab treatment for breast cancer in a managed care environmentJohn J Barron, Mark J Cziraky, Thomas Weisman, et al.
Breast Cancer Research and Treatment|August 4, 2007
Assessing the economic burden of breast cancer in a US managed care populationJohn J Barron, Ralph Quimbo, Prashant T Nikam, et al.
Journal of Pediatric Gastroenterology and Nutrition|November 22, 2007
Proton pump inhibitor utilization patterns in infantsJohn J Barron, Hiangkiat Tan, James Spalding, et al.
Journal of Breast Imaging|February 28, 2024
The Association Between Mammography Screening Frequency and Breast Cancer Treatment and Outcomes: A Retrospective Cohort StudyYing Liu, Aliza S Gordon, Michael Eleff, et al.
Plos One|March 29, 2018
Length of hospitalization and mortality for bleeding during treatment with warfarin, dabigatran, or rivaroxabanBlake Charlton, Gboyega Adeboyeje, John J Barron, et al.
JCO Oncology Practice|March 11, 2020
Use of Optimal Evidence-Based Anticancer Drug Regimens in Physician Offices Versus Hospital Outpatient FacilitiesEzra Fishman, Michael J Fisch, Ying Liu, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 22, 2022
Immune checkpoint inhibitors: immune-related adverse events, healthcare utilization, and costs among commercial and Medicare Advantage patientsKrishna S Gunturu, Timothy T Pham, Sonali Shambhu, et al.
The American Journal of Managed Care|September 27, 2012
Impact of medical homes on quality, healthcare utilization, and costsAndrea DeVries, Chia-Hsuan Winnie Li, Gayathri Sridhar, et al.
Pageof 2